Actively Recruiting
Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery
Led by Saint Petersburg State University, Russia · Updated on 2025-01-27
1373
Participants Needed
2
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.
CONDITIONS
Official Title
Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hospital performs at least 250 open heart surgeries per year
- More than 95% of hospital physicians treating adult patients (over 18 years) agree to follow the study's fibrinolysis inhibitor use protocol
You will not qualify if you...
- Hospital does not meet the inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Cardiac surgery department, Saint-Petersburg state university hospital
Saint Petersburg, Russia
Actively Recruiting
2
St. Petersburg State University Hospital
Saint Petersburg, Russia
Not Yet Recruiting
Research Team
S
Sergey Efremov, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here